Adán Manuel Piña-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adán Manuel Piña-González has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Rivera-Ramírez
Laboratorio de Estudios Ecogenómicos, Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico
1 shared publication - Dafne Arellano-Maciel
Laboratorio de Biología Computacional y Virómica Integrativa, Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico
1 shared publication - Efren Hernandez-Baltazar
Laboratorio de Tecnología Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico
1 shared publication - Gamaliel López-Leal
Laboratorio de Biología Computacional y Virómica Integrativa, Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico
1 shared publication - Nallelyt Segundo-Arizmendi
Laboratorio de Microbiología y Parasitología, Facultad de Farmacia de la, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico
1 shared publication
Latest Publications
- Open Access
- 7 January 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (1) , 100
Bacteriophages: A Challenge for Antimicrobial Therapy
Phage therapy, which involves the use of bacteriophages (phages) to combat bacterial infections, is emerging as a promising approach to address the escalating threat posed by multidrug-resistant (MDR) bacteria. This brief review examines the historical background and recent advancements in phage research, focusing on their genomics, interactions with host bacteria, and progress in medical and biotechnological applications. Additionally, we expose key aspects of the mechanisms of action, and therapeutic uses of phage considerations in treating MDR bacterial infections are discussed, particularly in the context of infections related to virus–bacteria interactions.
- 7 January 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (1) , 100
Open AccessBacteriophages: A Challenge for Antimicrobial Therapy
Phage therapy, which involves the use of bacteriophages (phages) to combat bacterial infections, is emerging as a promising approach to address the escalating threat posed by multidrug-resistant (MDR) bacteria. This brief review examines the historical background and recent advancements in phage research, focusing on their genomics, interactions with host bacteria, and progress in medical and biotechnological applications. Additionally, we expose key aspects of the mechanisms of action, and therapeutic uses of phage considerations in treating MDR bacterial infections are discussed, particularly in the context of infections related to virus–bacteria interactions.